Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. 2011

Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
Department of Pharmacology, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla, Thailand. somchai.sr@psu.ac.th

OBJECTIVE To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers. METHODS Ten healthy male volunteers were assigned into a 2-sequence, 3-period pharmacokinetic interaction study. In phase 1, all subjects were randomly assigned to receive 500 mg of ciprofloxacin alone and 200 mg of itraconazole alone twice daily for 7 days with a 14 day wash-out period in a crossover design. Phase 2 was performed 14 days after finishing phase 1, all subjects received 500 mg of ciprofloxacin in combination with 200 mg of itraconazole twice daily for 7 days. Ciprofloxacin and itraconazole pharmacokinetics were studied and adverse effects noted. RESULTS Ciprofloxacin significantly increased the C(max) and AUC(0 - ∞) of itraconazole by 53.13% and 82.46%, respectively. The half-life and CL of itraconazole were not changed significantly. The combination of itraconazole and ciprofloxacin could therefore result in an increase in adverse drug reactions. Conversely, itraconazole had no significant effect on the pharmacokinetics of ciprofloxacin. CONCLUSIONS Ciprofloxacin decreases the metabolism of itraconazole, most likely through inhibition of CYP3A4. The dosage of itraconazole should be reduced and its therapeutic outcome should be monitored closely when these two agents are concomitantly administered.

UI MeSH Term Description Entries
D008297 Male Males
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D017964 Itraconazole A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis. Orungal,R-51211,Sporanox,R 51211,R51211

Related Publications

Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
January 2011, European journal of drug metabolism and pharmacokinetics,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
July 1997, Indian journal of experimental biology,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
February 1996, Journal of clinical pharmacology,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
April 2000, Antimicrobial agents and chemotherapy,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
January 2018, Drug design, development and therapy,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
August 2023, Clinical and translational science,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
October 2002, Clinical pharmacology and therapeutics,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
January 2023, Drug design, development and therapy,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
August 2007, Journal of clinical pharmacology,
Somchai Sriwiriyajan, and Maseetoh Samaeng, and Wibool Ridtitid, and Werawath Mahatthanatrakul, and Malinee Wongnawa
July 2019, Advances in therapy,
Copied contents to your clipboard!